It has been one hot summer, especially here in the Dallas-Fort Worth, Texas, area. We saw a record-breaking streak of consecutive days over 100 °F and without rain.
With the summer months sweltering on, the editors and contributors of Contemporary OB/GYN® have been hard at work carefully crafting a great issue that touches upon a variety of subjects within obstetrics and gynecology.
There are several excellent must-read articles this month:
The cover story is an article by Melissa M. Mauskar, MD; Hunter J. Pyle, BBA; and Audrey K. Rutherford, MD, on vulvovaginal dermatology essentials needed every day to accurately identify various vulvar conditions and determine the appropriate treatment. the authors also provide information on how to best approach patients with vulvovaginal concerns in the clinic.
The Contraception section article, written by Danielle M. Alm, PharmD, BCPs, BCPPs; Reina Puri; and Christine Payne, takes a deep dive into the various contraceptives on the market and describes some best practices for discussing birth control with adolescent patients.
The Practice Matters column by Brian K. Iriye, MD; and James D. Keller, MD, provides thoughtful and informative tips on how to make meetings both effective and efficient.
The Life Transitions section explains the latest phase 3 data for fezolinetant (Astellas Pharma) to treat moderate to severe vasomotor symptoms associated with menopause. The data were presented at the American College of Obstetricians and Gynecologists' Annual Clinical and Scientific Meeting in May 2022 in san Diego, California.
Finally, the Well Woman section features an article by Bertie Geng, MD; and Alla Vash-Margita, MD, about cervical cancer screening guidelines in adolescents. And although average-risk adolescents don’t need Papanicolaou tests, this article gives an update on special populations of adolescent patients who do.
So, as you sit back, relax, and read this August issue of Contemporary OB/GYN® (I hope by a pool or in the shade), please let me know whether there are any topics you would be interested in reading about. Email me at cspong@mjhlifesciences.com.
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More